Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients

Clinical Neurophysiology

Volumn 124, Issue 5, 2013, Pages 837-850

  Babiloni, Claudio ^a,b   Del Percio, Claudio ^b   Bordet, Regis ^c   Bourriez, Jean Luis ^c   Bentivoglio, Marina ^d   Payoux, Pierre ^e   Derambure, Philippe ^c   Dix, Sophie ^f   Infarinato, Francesco ^b   Lizio, Roberta ^b   Triggiani, Antonio Ivano ^a   Richardson, Jill C ^g   Rossini, Paolo M ^b,h  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIV LILLE   (France)

^d UNIVERSITY OF VERONA   (Italy)

^e INSERM   (France)

^f ELI LILLY AND COMPANY   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer's disease; Drug treatments; Electroencephalography (EEG)

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; RIVASTIGMINE; TACRINE;

ALPHA RHYTHM; ALZHEIMER DISEASE; CLINICAL PROTOCOL; COGNITION; DELTA RHYTHM; DRUG EFFECT; DRUG SCREENING; ELECTROENCEPHALOGRAM; HUMAN; PRIORITY JOURNAL; PRODROMAL SYMPTOM; REVIEW; SINGLE DRUG DOSE; SPECTROSCOPY; THETA RHYTHM; TREATMENT RESPONSE;

ALPHA RHYTHM; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; COGNITION; ELECTROENCEPHALOGRAPHY; HUMANS; MEMANTINE;

EID: 84876124919     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2012.09.017     Document Type: Review

References (180)

1. Adler G., Brassen S. Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology 2001, 43:273-276.
2. Adler G., Brassen S., Chwalek K., Dieter B., Teufel M. Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 2004, 75:292-294.
3. Ala T.A., Hughes L.F., Kyrouac G.A., Ghobrial M.W., Elble R.J. The mini-mental state exam may help in the differentiation of dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2003, 18:855-856.
4. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
5. Alhainen K., Partanen J., Reinikainen K., Laulumaa V., Soininen H., Airaksinen M., et al. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett 1991, 130:46-48.
6. Alhainen K., Riekkinen P.J. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand Suppl 1993, 149:16-21.
7. Ames D.J., Bhathal P.S., Davies B.M., Fraser J.R. Hepatotoxicity of tetrahydroaminoacridine. Lancet 1988, 1:887.
8. Areosa S.A., Sherriff F., McShane R. Memantine for dementia. Cochrane Database Syst Rev 2005, (2):CD003154.
9. Babiloni C., Binetti G., Cassetta E., Cerboneschi D., Dal Forno G., Del Percio C., et al. Mapping distributed sources of cortical rhythms in mild Alzheimer's disease. A multicentric EEG study. Neuroimage 2004, 22:57-67.
10. Babiloni C., Binetti G., Cassetta E., Dal Forno G., Del Percio C., Ferreri F. Sources of cortical rhythms change as a function of cognitive impairment in pathological aging: a multicenter study. Clin Neurophysiol 2006, 117:252-268.
11. Babiloni C., Benussi L., Binetti G., Cassetta E., Dal Forno G., Del Percio C., et al. Apolipoprotein E and alpha brain rhythms in mild cognitive impairment: a multicentric electroencephalogram study. Ann Neurol 2006, 59:323-334.
12. Babiloni C., Benussi L., Binetti G., Bosco P., Busonero G., Cesaretti S., et al. Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: a multicentric study. Neuroimage 2006, 29:948-964.
13. Babiloni C., Frisoni G., Steriade M., Bresciani L., Binetti G., Del Percio C., et al. Frontal white matter volume and delta EEG sources negatively correlate in awake subjects with mild cognitive impairment and Alzheimer's disease. Clin Neurophysiol 2006, 117:1113-1129.
14. Babiloni C., Cassetta E., Dal Forno G., Del Percio C., Ferreri F., Ferri R., et al. Donepezil effects on sources of cortical rhythms in mild Alzheimer's disease: responders vs. non-responders. Neuroimage 2006, 31:1650-1665.
15. Babiloni C., Ferri R., Binetti G., Cassarino A., Dal Forno G., Ercolani M., et al. Fronto-parietal coupling of brain rhythms in mild cognitive impairment: a multicentric EEG study. Brain Res Bull 2006, 69:63-73.
16. Babiloni C., Cassetta E., Binetti G., Tombini M., Del Percio C., Ferreri F., et al. Resting EEG sources correlate with attentional span in mild cognitive impairment and Alzheimer's disease. Eur J Neurosci 2007, 25:3742-3757.
17. Babiloni C., Squitti R., Del Percio C., Cassetta E., Ventriglia M.C., Ferreri F., et al. Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clin Neurophysiol 2007, 118:1244-1260.
18. Babiloni C., Bosco P., Ghidoni R., Del Percio C., Squitti R., Binetti G., et al. Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study. Neuroscience 2007, 145:942-954.
19. Babiloni C., Frisoni G.B., Pievani M., Vecchio F., Infarinato F., Geroldi C., et al. White matter vascular lesions are related to parietal-to-frontal coupling of EEG rhythms in mild cognitive impairment. Hum Brain Mapp 2008, 29:1355-1367.
20. Babiloni C., Frisoni G.B., Pievani M., Toscano L., Del Percio C., Geroldi C., et al. White-matter vascular lesions correlate with alpha EEG sources in mild cognitive impairment. Neuropsychologia 2008, 46:1707-1720.
21. Babiloni C., Frisoni G.B., Pievani M., Vecchio F., Lizio R., Buttiglione M., et al. Hippocampal volume and cortical sources of EEG alpha rhythms in mild cognitive impairment and Alzheimer disease. Neuroimage 2009, 44:123-135.
22. Babiloni C., Pievani M., Vecchio F., Geroldi C., Eusebi F., Fracassi C., et al. White-matter lesions along the cholinergic tracts are related to cortical sources of EEG rhythms in amnesic mild cognitive impairment. Hum Brain Mapp 2009, 30:1431-1443.
23. Babiloni C., Pizzella V., Gratta C.D., Ferretti A., Romani G.L. Fundamentals of electroencephalography, magnetoencephalography, and functional magnetic resonance imaging. Int Rev Neurobiol 2009, 86:67-80.
24. Babiloni C., Frisoni G.B., Vecchio F., Pievani M., Geroldi C., De Carli C., et al. Global functional coupling of resting EEG rhythms is related to white-matter lesions along the cholinergic tracts in subjects with amnesic mild cognitive impairment. J Alzheimers Dis 2010, 19:859-1871.
25. Babiloni C., Visser P.J., Frisoni G., De Deyn P.P., Bresciani L., Jelic V., et al. Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiol Aging 2010, 31:1787-1798.
26. Babiloni C., Frisoni G.B., Vecchio F., Lizio R., Pievani M., Cristina G., et al. Stability of clinical condition in mild cognitive impairment is related to cortical sources of alpha rhythms: an electroencephalographic study. Hum Brain Mapp 2011, 32:1916-1931.
27. Babiloni C., Lizio R., Carducci F., Vecchio F., Redolfi A., Marino S., et al. Resting state cortical electroencephalographic rhythms and white matter vascular lesions in subjects with Alzheimer's disease: an Italian multicenter study. J Alzheimers Dis 2011, 26:331-346.
28. Babiloni C., De Pandis M.F., Vecchio F., Buffo P., Sorpresi F., Frisoni G.B., et al. Cortical sources of resting state electroencephalographic rhythms in Parkinson's disease related dementia and Alzheimer's disease. Clin Neurophysiol 2011, 122:2355-2364.
29. Babiloni C., Carducci F., Lizio R., Vecchio F., Baglieri A., Bernardini S., et al. Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp 2012, 10.1002/hbm.22005.
30. Başar E., Güntekin B., Tülay E., Yener G.G. Evoked and event related coherence of Alzheimer patients manifest differentiation of sensory-cognitive networks. Brain Res 2010, 357:79-90.
31. Basar-Eroglu C., Strüber D., Schürmann M., Stadler M., Basar E. Gammaband responses in the brain: a short review of psychophysiological correlates and functional significance. Int J Psychophysiol 1996, 24:101-112.
32. Berger H. über das Elektroenkephalogramm des Menschen. Archiv für Psychiatrie und Nervenkrankheiten 1929, 87:527-570.
33. Besthorn C., Zerfass R., Geiger-Kabisch C., Sattel H., Daniel S., Schreiter-Gasser U., et al. Discrimination of Alzheimer's disease and normal aging by EEG data. Electroencephalogr Clin Neurophysiol 1997, 103:241-248.
34. Bianchetti A., Rozzini R., Trabucchi M. Effects of acetyl-l-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 2003, 19:350-353.
35. Birks J.S., Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003, CD001190.
36. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
37. Brassen S., Adler G. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial. Pharmacopsychiatry 2003, 36:304-308.
38. Brooks J., Yesavage J., Taylor J., Friedman L., Tanks E.D., Luby V., et al. Cognitive decline in Alzheimer's disease: elaborating on the nature of the longitudinal factor structure of the mini-mental state examination. Int Psychogeriatr 1993, 5:135-145.
39. Burns A., Russell E., Page S. New drugs for Alzheimer's disease. Br J Psychiatry 1999, 174:476-479.
40. Buzsáki G., Gage F.H. The cholinergic nucleus basalis: a key structure in neocortical arousal. EXS 1989, 57:159-171.
41. Cappell J., Herrmann N., Cornish S., Lanctôt K.L. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 2010, 24:909-927.
42. Caravaglios G., Costanzo E., Palermo F., Muscoso E.G. Decreased amplitude of auditory event-related delta responses in Alzheimer's disease. Int J Psychophysiol 2008, 70:23-32.
43. Caravaglios G., Castro G., Costanzo E., Di Maria G., Mancuso D., Muscoso E.G. Θ power responses in mild Alzheimer's disease during an auditory oddball paradigm: lack of theta enhancement during stimulus processing. J Neural Transm 2010, 117:1195-1208.
44. Celesia G.G., Jasper H.H. Acetylcholine released from cerebral cortex in relation to state of activation. Neurology 1966, 16:1053-1063.
45. Chiaramonti R., Muscas G.C., Paganini M., Muller T.J., Fallgatter A.J., Versari A., et al. Correlations of topographical EEG features with clinical severity in mild and moderate dementia of Alzheimer type. Neuropsychobiology 1997, 36:153-158.
46. Christie J.E., Shering A., Ferguson J., Glen A.I. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981, 138:46-50.
47. Clark C.M., Xie S., Chittams J., Ewbank D., Peskind E., Galasko D., et al. Cerebrospinal fluid tau and betaamyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 2003, 60:1696-1702.
48. Crum R.M., Anthony J.C., Bassett S.S., Folstein M.F. Population-based norms for the mini mental state examination by age and educational level. JAMA 1993, 18:2386-2391.
49. Cuculic Z., Bost K., Himwich H.E. An examination of a possible cortical cholinergic link in the EEG arousal reaction. Prog Brain Res 1968, 28:27-39.
50. Daan S., Beersma D.G., Borbély A.A. Timing of human sleep: recovery process gated by a circadian pacemaker. Am J Physiol 1984, 246:161-183.
51. Daulatzai M.A. Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease. J Alzheimers Dis 2010, 20:355-367.
52. DeJong R., Osterlund O.W., Roy G.W. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1989, 11:545-554.
53. Diekelmann S., Born J. The memory function of sleep. Nat Rev Neurosci 2010, 11:114-126.
54. Dierks T., Jelic V., Pascual-Marqui R.D., Wahlund L.O., Julin P., Linden D.E.J., et al. A spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin Neurophysiol 2000, 111:1817-1824.
55. Dimpfel W. Pharmacological modulation of cholinergic brain activity and its reflection in special EEG frequency ranges from various brain areas in the freely moving rat (Tele-Stereo-EEG). Eur Neuropsychopharmacol 2005, 15:673-682.
56. Dringenberg H.C., Diavolitsis P., Noseworthy P.A. Effect of tacrine on EEG slowing in the rat: enhancement by concurrent monoamine therapy. Neurobiol Aging 2000, 21:135-143.
57. Dringenberg H.C., Laporte P.P., Diavolitsis P. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. Neuroreport 2000, 11:3513-3516.
58. Dringenberg H.C., Rubenstein M.L., Solty H., Tomaszek S., Bruce A. Electroencephalographic activation by tacrine, deprenyl, and quipazine: cholinergic vs. non-cholinergic contributions. Eur J Pharmacol 2002, 447:43-50.
59. Du Y., Zhang J.X., Xiao Z., Wu R. Neural systems and time course of proactive interference in working memory. Conf Proc IEEE Eng Med Biol Soc 2007, 1136-1139.
60. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
61. Elfgren C., Brun A., Gustafson L., Johanson A., Minton L., Passant U., et al. Neuropsychological tests as discriminators between dementia of Alzheimer's type and frontotemporal dementia. Int Geriatr Psychiatry 1994, 9:635-642.
62. Engel A.K., Fries P., Singer W. Dynamic predictions: oscillations and synchrony in top-down processing. Nat Rev Neurosci 2000, 2:704-716.
63. Enz A., Floersheim P. Cholinesterase inhibitors: an overview of their mechanism of action. Alzheimer's disease: from molecular biology to therapy 1996, 211-215. Birkhauser, Boston, MA. R. Becker, E. Giacobini (Eds.).
64. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
65. Farlow M., Gracon S.I., Hershey L.A., Lewis K.W., Sadowsky C.H., Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA 1992, 268:2523-2529.
66. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr 2002, 14:93-126.
67. Feldman H., Gauthier S., Hecker J., Vellas B., Emir B., Mastey V., et al. Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003, 51:737-744.
68. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P. Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001, 57:613-620.
69. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
70. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010, 6:67-77.
71. Fuchs M., Kastner J., Wagner M., Hawes S., Ebersole J.S. A standardized boundary element method volume conductor model. Clin Neurophysiol 2002, 113:702-712.
72. Funderburk W.H., Case T.J. The effect of atropine on cortical potentials. Electroencephalogr Clin Neurophysiol 1951, 3:213-223.
73. Galasko D., Bennett D., Sano M., Ernesto C., Thomas R., Grundman M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 11:S33-539.
74. Gauthier S., Loft H., Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008, 23:537-545.
75. Geldmacher D.S., Provenzano G., McRae T., Mastey V., Ieni J.R. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003, 51:937-944.
76. Gelinas I., Gauthier L., McIntyre M., Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999, 53:471-481.
77. Giannitrapani D., Collins J. EEG differentiation between Alzheimer's and non-Alzheimer's dementias. The EEG of mental activities 1988, 50-65. Karger.
78. Giannitrapani D., Collins J., Vassiliadis D. The EEG spectra of Alzheimer's disease. Int J Psychophysiol 1991, 10:259-269.
79. Giaquinto S., Nolfe G. The EEG in the normal elderly: a contribution to the interpretation of aging and dementia. Electroencephalogr Clin Neurophysiol 1986, 63:540-546.
80. Gianotti L.R., Künig G., Faber P.L., Lehmann D., Pascual-Marqui R.D., Kochi K., et al. Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease. Psychopharmacology (Berl) 2008, 198:323-332.
81. Goodin D.S., Aminoff M.J. Electrophysiological differences between subtypes of dementia. Brain 1986, 109:1102-1113.
82. Grech R., Cassar T., Muscat J., Camilleri K.P., Fabri S.G., Zervakis M., et al. Review on solving the inverse problem in EEG source analysis. J Neuroeng Rehabil 2008, 5:25.
83. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004, 61:59-66.
84. Hanyu H., Shimizu T., Tanaka Y., Takasaki M., Koizumi K., Abe K. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2003, 15:177-182.
85. Hsiung G.Y., Feldman H.H. Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opin Pharmacother 2008, 9:2575-2582.
86. Huang C., Wahlund L., Dierks T., Julin P., Winblad B., Jelic V. Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 2000, 111:1961-1967.
87. Hutton M., Dix S., DeMattos R., May P., Siemers E. The challenge of Alzheimer's disease therapeutic development: an Eli Lilly view. Nature 2011, 475:S44-S48.
88. Ihl R., Frolich L., Dierks T., Martin E.A., Maurer K. Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Res 1992, 44:93-106.
89. Ihl R., Dierks T., Martin E.M., Froölich L., Maurer K. Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Biol Psychiatry 1996, 39:319-325.
90. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
91. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
92. Jagust W.J., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69:871-877.
93. Jelic V., Dierks T., Amberla K., Almkvist O., Winblad B., Nordberg A. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neurosci Lett 1998, 254:85-88.
94. John E.R. The role of quantitative EEG topographic mapping or 'neurometrics' in the diagnosis of psychiatric and neurological disorders. Electroencephalogr Clin Neurophysiol 1989, 73:2-4.
95. Jones B.E., Cuello A.C. Afferents to the basal forebrain cholinergic cell area from pontomesencephalic-catecholamine, serotonin, and acetylcholine-neurons. Neuroscience 1989, 31:37-61.
96. Jurcak V., Okamoto M., Singh A., Dan I. Virtual 10-20 measurement on MR images for inter-modal linking of transcranial and tomographic neuroimaging methods. Neuroimage 2005, 26:1184-1192.
97. Kaduszkiewicz H., Zimmermann T., Beck-Bornholdt H.P., van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005, 331:321-327.
98. Kirk A. Target symptoms and outcome measures: cognition. Can J Neurol Sci 2007, 34(Suppl. 1):S42-S46.
99. Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance. a review and analysis. Brain Res Brain Res Rev 1999, 29:169-195.
100. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound B. Ann Neurol 2004, 55:306-319.
101. Knott V., Mohr E., Mahoney C., Ilivitsky V. Pharmaco-EEG test dose response predicts cholinesterase inhibitor treatment outcome in Alzheimer's disease. Methods Find Exp Clin Pharmacol 2000, 22:115-122.
102. Knott V., Engeland C., Mohr E., Mahoney C., Ilivitsky V. Acute nicotine administration in Alzheimer's disease: an exploratory EEG study. Neuropsychobiology 2000, 41:210-220.
103. Kogan E.A., Korczyn A.D., Virchovsky R.G., Klimovizky S.Sh., Treves T.A., Neufeld M.Y. EEG changes during long-term treatment with donepezil in Alzheimer's disease patients. J Neural Transm 2001, 108:1167-1173.
104. Kornhuber J., Weller M. Psychotogenicity and N-methyl-d-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997, 41:135-144.
105. Kunik M.E., Huffman J.C., Bharani N., Hillman S.L., Molinari V.A., Orengo C.A. Behavioural disturbances in geropsychiatric inpatients across dementia types. J Geriatr Psychiatry Neurol 2000, 13:49-52.
106. Lanctôt K.L., Herrmann N., LouLou M.M. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci 2003, 28:13-26.
107. Lee V.M., Brunden K.R., Hutton M., Trojanowski J.Q. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 2011, 1:a006437.
108. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006, 5:160-170.
109. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
110. Mecocci P., Bladström A., Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 2009, 24:532-538.
111. Mesulam M., Shaw P., Mash D., Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004, 55:815-828.
112. Metherate R., Cox C.L., Ashe J.H. Cellular bases of neocortical activation: modulation of neural oscillations by the nucleus basalis and endogenous acetylcholine. J Neurosci 1992, 12:4701-4711.
113. Michel C.M., Murray M.M., Lantz G., Gonzalez S., Spinelli L., Grave de Peralta R. EEG source imaging. Clin Neurophysiol 2004, 115:2195-2222.
114. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997, 42:85-94.
115. Mohs R.C., Davis B.M., Greenwald B.S., Mathé A.A., Johns C.A., Horvath T.B., et al. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies. J Am Geriatr Soc 1985, 33:749-757.
116. Mohs R.C., Doody R.S., Morris J.C., Ieni J.R., Rogers S.L., Perdomo C.A., et al. A 1-year, placebo-controlled preservation of function survival study of donepezildonepezil in AD patients. Neurology 2001, 57:481-488.
117. Mohs R.C., Rosen W.G., Davis K.L. The Alzheimer's Disease Assessment Scale: an instrument of assessing treatment efficacy. Psychopharmacol Bull 1983, 19:448-450.
118. Moraes Wdos S., Poyares D.R., Guilleminault C., Ramos L.R., Bertolucci P.H., Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 2006, 29:199-205.
119. Nobili F., Copello F., Vitali P., Prastaro T., Carozzo S., Perego G., et al. Timing of disease progression by quantitative EEG in Alzheimer's patients. J Clin Neurophysiol 1999, 16:566-573.
120. Nunez P.L., Srinivasan R. A theoretical basis for standing and traveling brain waves measured with human EEG with implications for an integrated consciousness. Clin Neurophysiol 2006, 117:2424-2435.
121. Nunez P.L., Wingeier B.M., Silberstein R.B. Spatial-temporal structures of human alpha rhythms: theory, microcurrent sources, multiscale measurements, and global binding of local networks. Hum Brain Mapp 2001, 13:125-164.
122. Nunez P.L. Toward a quantitative description of large-scale neocortical dynamic function and EEG. Behav Brain Sci 2000, 23:371-398.
123. Onofrj M., Thomas A., Iacono D., Luciano A.L., Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol 2003, 26:239-251.
124. Pascual-Marqui R.D., Esslen M., Kochi K., Lehmann D. Functional imaging with low-resolution brain electromagnetic tomography (LORETA): a review. Methods Find Exp Clin Pharmacol 2002, 24:91-95.
125. Pascual-Marqui R.D., Lehmann D., Koenig T., Kochi K., Merlo M.C., Hell D., et al. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. Psychiatry Res 1999, 90:169-179.
126. Pascual-Marqui R.D., Michel C.M., Lehmann D. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int J Psychophysiol 1994, 18:49-65.
127. Petersen R.C., Smith G.E., Ivnik R.J., Tangalos E.G., Schaid D.J., Thibodeau S.N., et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995, 273:1274-1278.
128. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
129. Petersen R.C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 2000, 15:93-101.
130. Porsteinsson A.P., Grossberg G.T., Mintzer J. Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008, 5:83-89.
131. Reeves R.R., Struve F.A., Patrick G. The effects of donepezil on quantitative EEG in patients with Alzheimer's disease. Clin Electroencephalogr 2002, 33:93-96.
132. Reisberg B., Ferris S., Anand R., Mir R., Geibel V., DeLeon M.J., et al. Functional staging of dementia of the Alzheimer's type. Ann NY Acad Sci 1984, 435:481-483.
133. Reisberg B., Ferris S.H., Franssen E.H., Shulman E., Monteiro L., Sclan S.G., et al. Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study. Int Psychogeriatr 1996, 8:291-311.
134. Relkin N.R., Reichman W.E., Orazem J., McRae T. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003, 16:15-24.
135. Repantis D., Laisney O., Heuser I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 2010, 61:473-481.
136. Rodriguez G., Vitali P., De Leo C., De Carli F., Girtler N., Nobili F. Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy. Neuropsychobiology 2002, 46:49-56.
137. Rodriguez G., Vitali P., Canfora M., Calvini P., Girtler N., De Leo C., et al. Quantitative EEG and perfusional single photon emission computed tomography correlation during long-term donepezil therapy in Alzheimer's disease. Clin Neurophysiol 2004, 115:39-49.
138. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984, 141:1356-1364.
139. Rosenwasser A.M. Principles and Practices of Sleep Medicine 2005, 351-362. Saunders, New York. M.H. Kryger, T. Roth, W. Dement (Eds.).
140. Rossetti A.O., Kaplan P.W. Seizure semiology: an overview of the 'inverse problem'. Eur Neurol 2010, 63:3-10.
141. Rossini P.M., Del Percio C., Pasqualetti P., Cassetta E., Binetti G., Dal Forno G., et al. Conversion from mild cognitive impairment to Alzheimer's disease is predicted by sources and coherence of brain electroencephalography rhythms. Neuroscience 2006, 143:793-803.
142. Rossini P.M., Rossi S., Babiloni C., Polich J. Clinical neurophysiology of aging brain: from normal aging to neurodegeneration. Prog Neurobiol 2007, 83:375-400.
143. Rossini P.M. Implications of brain plasticity to brain-machine interfaces operation a potential paradox?. Int Rev Neurobiol 2009, 86:81-90.
144. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
145. Saletu B., Anderer P., Saletu-Zyhlarz G.M., Pascual-Marqui R.D. EEG mapping and low-resolution brain electromagnetic tomography (LORETA) in diagnosis and therapy of psychiatric disorders: evidence for a key-lock principle. Clin EEG Neurosci 2005, 36:108-115.
146. Salmon D.P., Bondi M.W. Neuropsychology of Alzheimer's disease. Alzheimer disease 1999, 39-56. Lippincott Williams & Wilkens, Philadelphia, PA. 2nd ed. R.D. Terry, R. Katzman, K.L. Bick, S.S. Sisodia (Eds.).
147. Saxton J., Swihart A.A. Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med 1989, 5:531-543.
148. Schmitt F.A., Cragar D., Ashford J.W., Resiberg B., Ferris S., Mobius H.J., et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl 2002, 62:135-148.
149. Schoonenboom N.S., van der Flier W.M., Blankenstein M.A., Bouwman F.H., Van Kamp G.J., Barkhof F., et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008, 29:669-675.
150. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., et al. Alzheimer's Disease Neuroimaging Initiative. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
151. Sekihara K., Sahani M., Nagarajan S.S. Localization bias and spatial resolution of adaptive and non-adaptive spatial filters for MEG source reconstruction. Neuroimage 2005, 25:1056-1067.
152. Semba K., Fibiger H.C. Organization of central cholinergic systems. Prog Brain Res 1989, 79:37-63.
153. Shen Z.X. Brain cholinesterases. III. Future perspectives of AD research and clinical practice. Med Hypotheses 2004, 63:298-307.
154. Schreiter-Gasser U., Gasser T., Ziegler P. Quantitative EEG analysis in early onset Alzheimer's disease: a controlled study. Electroencephalogr Clin Neurophysiol 1993, 86:15-22.
155. Signorino M., Pucci E., Belardinelli N., Nolfe G., Angeleri F. EEG spectral analysis in vascular and Alzheimer dementia. Electroencephalogr Clin Neurophysiol 1995, 94:313-325.
156. Silbert L.C., Quinn J.F., Moore M.M., Corbridge E., Ball M.J., Murdoch G., et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003, 61:487-492.
157. Sneddon R., Shankle W.R., Hara J., Rodriquez A., Hoffman D., Saha U. QEEG monitoring of Alzheimer's disease treatment: a preliminary report of three case studies. Clin EEG Neurosci 2006, 37:54-59.
158. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
159. Steriade M., Nuñez A., Amzica F. Intracellular analysis of relations between the slow (<1Hz) neocortical oscillation and other sleep rhythms of the electroencephalogram. J Neurosci 1993, 13:3266-3283.
160. Steriade M. Cholinergic blockage of network- and intrinsically generated slow oscillations promotes waking and REM sleep activity patterns in thalamic and cortical neurons. Prog Brain Res 1993, 98:345-355.
161. Steriade M. Principles and practice of sleep medicine 2005, 101-119. Elsevier, Philidelphia, PA. M.H. Kryger, T. Roth, W.C. Dement (Eds.).
162. Stern Y., Sano M., Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988, 38:1837-1841.
163. Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 1986, 315:1241-1245.
164. Talairach J., Tournoux P. Co-planar stereotaxic atlas of the human brain 1988, Thieme, Stuttgart.
165. Tanaka Y., Hanyu H., Sakurai H., Takasaki M., Abe K. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dement Geriatr Cogn Disord 2003, 16:119-125.
166. Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H., et al. Cerebrospinal fluid β-amyloid forty-two and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009, 66:382-389.
167. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S. Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324.
168. Teri L., Hughes J.P., Larson E.B. Cognitive deterioration in Alzheimer's disease: behavioural and health factors. J Gerontol 1990, 45:58-63.
169. Tononi G. Slow wave homeostasis and synaptic plasticity. J Clin Sleep Med 2009, 5:S16-19.
170. Van de Pol L.A., Hensel A., van der Flier W.M., Visser P., Pijnenburg Y.A., Barkhof F., et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006, 77:439-442.
171. Verhey F.R., Houx P., Van Lang N., Huppert F., Stoppe G., Saerens J., et al. Cross-national comparison and validation of the Alzheimer's Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EUROHARPID). Int J Geriatr Psychiatry 2004, 19:41-50.
172. Vertes R.P. Brainstem afferents to the basal forebrain in the rat. Neuroscience 1988, 24:907-935.
173. Wagner M., Fuchs M., Kastner J. Evaluation of sLORETA in the presence of noise and multiple sources. Brain Topogr 2004, 16:277-280.
174. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994, 271:992-998.
175. Wilkinson D., Schindler R., Schwam E., Waldemar G., Jones R.W., Gauthier S., et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2009, 28:244-251.
176. Winblad B., Gauthier S., Aström D., Stender K. Memantine benefits functional abilities in moderate to severe Alzheimer's disease. J Nutr Health Aging 2010, 14:770-774.
177. Yener G.G., Güntekin B., Tülay E., Başar E. A comparative analysis of sensory visual evoked oscillations with visual cognitive event related oscillations in Alzheimer's disease. Neurosci Lett 2009, 462:193-197.
178. Yener G.G., Güntekin B., örken D.N., Tülay E., Forta H., Başar E. Auditory delta event-related oscillatory responses are decreased in Alzheimer's disease. Behav Neurol 2012, 25:3-11.
179. Zaborszky L. Afferent connections of the forebrain cholinergic projection neurons, with special reference to monoaminergic and peptidergic fibers. EXS 1989, 57:12-32.
180. Zarow C., Vinters H.V., Ellis W.G., Weiner M.W., Mungas D., White L., et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia. Ann Neurol 2005, 57:896-903.